<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Data Science, University of Texas at Austin, [3], 0000000419368710grid.47100.32Center for" exact="Infectious" post="Disease Modeling and Analysis, Yale School of Public Health,"/>
 <result pre="Science, University of Texas at Austin, [3], 0000000419368710grid.47100.32Center for Infectious" exact="Disease" post="Modeling and Analysis, Yale School of Public Health, [4],"/>
 <result pre="1936 9924grid.89336.37Department of Molecular Biosciences, John Ring LaMontagne Center for" exact="Infectious" post="Disease, Institute for Cellular and Molecular Biology, University of"/>
 <result pre="tolls. Baloxavir, the recently approved influenza antiviral, inhibits initiation of" exact="viral" post="mRNA synthesis, whereas oseltamivir, an older drug, inhibits release"/>
 <result pre="treatment on population-level incidence using a new model that links" exact="viral" post="load dynamics from clinical trial data to between-host transmission."/>
 <result pre="trial data to between-host transmission. We estimate that ~22 million" exact="infections" post="and &amp;gt;6,000 deaths would have been averted in the 2017–2018"/>
 <result pre="avert substantial influenza morbidity and mortality every year. Subject terms" exact="Diseases" post="Health care Funding Models of Infectious Disease Agent Study"/>
 <result pre="every year. Subject terms Diseases Health care Funding Models of" exact="Infectious" post="Disease Agent Study (MIDAS) program grant number U01 GM087719"/>
 <result pre="year. Subject terms Diseases Health care Funding Models of Infectious" exact="Disease" post="Agent Study (MIDAS) program grant number U01 GM087719 Funding"/>
 <result pre="Introduction Influenza A and B viruses cause a highly contagious" exact="respiratory" post="disease in humans that kills 290,000–650,000 people worldwide every"/>
 <result pre="Influenza A and B viruses cause a highly contagious respiratory" exact="disease" post="in humans that kills 290,000–650,000 people worldwide every year1."/>
 <result pre="that kills 290,000–650,000 people worldwide every year1. Vaccination is the" exact="primary" post="means for controlling influenza transmission but is hampered by"/>
 <result pre="influenza transmission but is hampered by the variable efficacy and" exact="incomplete" post="population coverage of annual vaccines, and thus is not"/>
 <result pre="symptoms. Prior to 2018, the only approved influenza antivirals were" exact="viral" post="neuraminidase inhibitors2,3. Of these, only oseltamivir (Tamiflu) can be"/>
 <result pre="surface, which is the last step in the production of" exact="infectious" post="virus. Multiple oseltamivir treatments over 5 consecutive days are"/>
 <result pre="is the last step in the production of infectious virus." exact="Multiple" post="oseltamivir treatments over 5 consecutive days are required to"/>
 <result pre="inhibits an early step in virus replication, the initiation of" exact="viral" post="mRNA synthesis5–7. This initiation step requires cap-snatching, a mechanism"/>
 <result pre="This initiation step requires cap-snatching, a mechanism in which the" exact="viral" post="polymerase binds to the cap structure (m7GpppNm) at the"/>
 <result pre="the capped RNA fragments that serve as primers to initiate" exact="viral" post="mRNA synthesis. Because baloxavir almost completely inhibits the cap-dependent"/>
 <result pre="completely inhibits the cap-dependent endonuclease, little or no initiation of" exact="viral" post="mRNA synthesis occurs, and little or no virus is"/>
 <result pre="and a hierarchical mathematical model that links within-host dynamics of" exact="viral" post="load to between-host transmission. Our results indicate that scaling"/>
 <result pre="We estimated the efficacy with which oseltamivir and baloxavir inhibit" exact="viral" post="replication by fitting the model to the results of"/>
 <result pre="the results of a recent clinical trial8 that measured the" exact="viral" post="loads of 1014 influenza virus-infected patients after treatment with"/>
 <result pre="oseltamivir, baloxavir, or a placebo (Table 1). Our model produces" exact="viral" post="titer estimates similar to the clinical data, and, like"/>
 <result pre="within-host and between-host models to data. Parameter Median 95% CI" exact="lower" post="95% CI upper Antiviral efficacy \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts}"/>
 <result pre="models to data. Parameter Median 95% CI lower 95% CI" exact="upper" post="Antiviral efficacy \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs}"/>
 <result pre="\setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ for oseltamivir 0.89 0.88 0.90 Initial sensitive" exact="viral" post="load V0 (TCID50/ml) 258.2 3.3a 2268.9a Basic reproduction number"/>
 <result pre="G0–24 (hours after symptom onset, truncated at 24 h) G(4.0, 6.3)/2" exact="Delayed" post="distribution of treatment initiation times, G24–48 (hours after symptom"/>
 <result pre="to 24–48 h window) G(4.0, 6.3)/2 + 24 Distribution of time lag between" exact="infection" post="and symptom onset, L (hours) 24aL(0.37,0.41) aFor estimates derived"/>
 <result pre="annealing, we provide 95 percentile range rather than confidence intervals." exact="Viral" post="replication and antiviral efficacy are estimated via simulated annealing46"/>
 <result pre="seasonal influenza incidence data12. Parameters for distributions of time between" exact="infection" post="and symptom onset (lognormal) and from symptom onset to"/>
 <result pre="in Supplementary Tables 2 and 3. Fig. 1 Changes in" exact="viral" post="load following antiviral treatment. The estimated means and standard"/>
 <result pre="treatment on the transmission dynamics of influenza We incorporated this" exact="viral" post="replication model into a stochastic individual-based model of influenza"/>
 <result pre="influenza transmission that tracks the daily evolution of infectiousness with" exact="disease" post="progression. The infectiousness of a case at any given"/>
 <result pre="infectiousness of a case at any given time depends on" exact="viral" post="load, treatment status, and baseline transmission rates estimated from"/>
 <result pre="Consistent with previous studies14,15, we assume a logarithmic relationship between" exact="viral" post="load and infectiousness (Fig. 2). Unless otherwise specified, each"/>
 <result pre="within two days, whereas oseltamivir-treated patients are predicted to remain" exact="infectious" post="for ~4 or 5 days. Fig. 2 Early antiviral"/>
 <result pre="over 900,000 hospitalizations and more than 79,000 deaths16. In the" exact="absence of" post="scaling up antiviral coverage, the timing and magnitude of"/>
 <result pre="48 h after symptoms onset reduces the expected number of influenza" exact="infections" post="throughout the virus season by 38% or 26%, respectively."/>
 <result pre="respectively. We estimate the reduction in the number of overall" exact="infections" post="at other treatment levels, ranging from 10% to 50%"/>
 <result pre="calculated the basic reproduction number (R0), the average number of" exact="secondary" post="infections generated by a typical infectious case at the"/>
 <result pre="the basic reproduction number (R0), the average number of secondary" exact="infections" post="generated by a typical infectious case at the outset"/>
 <result pre="the average number of secondary infections generated by a typical" exact="infectious" post="case at the outset of the epidemic (Supplementary Table"/>
 <result pre="the 80% prediction interval across 1000 stochastic simulations. b Estimated" exact="total" post="attack rates in simulated intervention scenarios ranging from no"/>
 <result pre="stochastic simulation assumes a population of 10,000 individuals, with within-host" exact="viral" post="replication and between-host transmission parameters given in Table 1."/>
 <result pre="after symptoms onset results in a significantly greater reduction in" exact="total" post="incidence than treatment within the second 24 h window following"/>
 <result pre="treatment scenario is expected to avert 3.8 and 5.3 million" exact="infections" post="more than the delayed treatment scenario, respectively. We also"/>
 <result pre="dose after symptom onset. Values are areas between the log" exact="viral" post="titer curves shown in Fig. 2 for untreated and"/>
 <result pre="respectively, across 100 stochastic simulations for each treatment window. b" exact="Total" post="infections averted by treating the indicated percent of cases"/>
 <result pre="across 100 stochastic simulations for each treatment window. b Total" exact="infections" post="averted by treating the indicated percent of cases with"/>
 <result pre="~10,200 lives. Our results indicate that optimal reduction of overall" exact="infection" post="occurs when a significant number of infected cases are"/>
 <result pre="Consequently, efforts to accelerate the diagnosis and treatment of influenza" exact="infections" post="with antivirals such as baloxavir, including potentially cost-saving telemedicine23,"/>
 <result pre="attainable in future influenza epidemics. Influenza A viruses also cause" exact="periodic" post="widespread pandemics usually resulting in higher mortality rates24. The"/>
 <result pre="not modeled possible biases in the data with respect to" exact="disease" post="severity or timing of treatment. Future epidemiological studies and"/>
 <result pre="considered in our models. First, we have not considered that" exact="viral" post="kinetics and the efficacy of treatment may substantially vary"/>
 <result pre="of baloxavir-treated adults8, and in some cases prolonged symptoms and" exact="viral" post="shedding. Combination therapy with baloxavir and a neuraminidase inhibitor"/>
 <result pre="the infectiousness of a case is logarithmically related to their" exact="viral" post="load. Although there is little doubt that infectiousness and"/>
 <result pre="viral load. Although there is little doubt that infectiousness and" exact="viral" post="load are positively correlated, transmission also depends on contact"/>
 <result pre="rates can potentially spare millions of people from influenza virus" exact="infections" post="during epidemics, thereby substantially reducing hospitalizations, morbidity, and deaths."/>
 <result pre="telemedicine and the development of rapid, sensitive assays for influenza" exact="virus infection." post="Methods Our hierarchical method includes three steps (Supplementary Table"/>
 <result pre="A replication dynamics We applied a published model that includes" exact="viral" post="suppression by both the immune response and antiviral treatment10,11,"/>
 <result pre="\usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ denote the" exact="viral" post="replication rate, viral death rate, cell infection rate, growth"/>
 <result pre="\usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ denote the viral replication rate," exact="viral" post="death rate, cell infection rate, growth rate of the"/>
 <result pre="ϵ denote the viral replication rate, viral death rate, cell" exact="infection" post="rate, growth rate of the immune response, and the"/>
 <result pre="estimate all model parameters. We assumed that the time from" exact="infection" post="to symptom onset follows a lognormal distribution, L, and"/>
 <result pre="We do not explicitly consider other sources of heterogeneity in" exact="viral" post="replication or immune response rates. Although most of the"/>
 <result pre="14,15, we assume that infectiousness is a logarithmic function of" exact="viral" post="load, as given by \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb}"/>
 <result pre="where V(t) denotes the virus load at time t since" exact="infection" post="(Supplementary Section 2). To estimate total reduction in infectiousness"/>
 <result pre="at time t since infection (Supplementary Section 2). To estimate" exact="total" post="reduction in infectiousness attributable to treatment, we calculate the"/>
 <result pre="and WHO lab percent positive influenza tests12,13. We then incorporated" exact="viral" post="replication dynamics and antiviral treatment into a stochastic agent-based"/>
 <result pre="model (Supplementary Section 3). We replace the discrete exposed and" exact="symptomatic" post="states with continuously changing infectiousness from the moment of"/>
 <result pre="symptomatic states with continuously changing infectiousness from the moment of" exact="infection" post="that is governed by our within-host model. Exposed individuals"/>
 <result pre="that is governed by our within-host model. Exposed individuals become" exact="symptomatic" post="(and thus eligible for treatment) according to L; treated"/>
 <result pre="within a 48 h window following distribution G0–48 (unless otherwise specified);" exact="symptomatic" post="recover when their virus load falls below zero yielding"/>
 <result pre="recover when their virus load falls below zero yielding average" exact="infectious" post="periods of 9, 4, and 7 days, as infection"/>
 <result pre="average infectious periods of 9, 4, and 7 days, as" exact="infection" post="for untreated, baloxavir-treated, and oseltamivir-treated cases, respectively (assuming treatment"/>
 <result pre="cases, respectively (assuming treatment times follow G0–48). The force of" exact="infection" post="(the probability that a susceptible individual becomes exposed) is"/>
 <result pre="size and βj(t) is the transmission rate of the jth" exact="infectious" post="individual (symptomatic or treated) at time t, which is"/>
 <result pre="the individual’s infectiousness at time t based on the within-host" exact="viral" post="load model. Supplementary Section 6 addresses the assumptions and"/>
 <result pre="of a single simulation, we calculate the average number of" exact="secondary" post="cases produced by all individuals infected during the first"/>
 <result pre="repeatedly run baseline and treatment simulations in tandem, assuming a" exact="total" post="population of 10,000. For each pair i, we record"/>
 <result pre="10,000. For each pair i, we record the difference in" exact="total" post="incidence between the baseline and treatment simulations, di = I0 − It, the"/>
 <result pre="total incidence between the baseline and treatment simulations, di = I0 − It, the" exact="total" post="number of cases treated in the treatment simulation ni."/>
 <result pre="of di/I0 by a CDC reported estimated for number of" exact="infections" post="during the 2017–2018 influenza season12,13. DALYs averted To estimate"/>
 <result pre="treatment, we again pair baseline and treatment simulations. To translate" exact="infections" post="averted into healthy life years gained, we apply a"/>
 <result pre="L.A.M. would like to acknowledge funding from the Models of" exact="Infectious" post="Disease Agent Study (MIDAS) program grant number U01 GM087719."/>
 <result pre="would like to acknowledge funding from the Models of Infectious" exact="Disease" post="Agent Study (MIDAS) program grant number U01 GM087719. R.M.K."/>
 <result pre="2018). 5.PlotchSJBouloyMKrugRMTransfer of 5′-terminal cap of globin mRNA to influenza" exact="viral" post="complementary RNA during transcription in vitroProc. Natl Acad. Sci."/>
 <result pre="endonuclease cleaves capped RNAs to generate the primers that initiate" exact="viral" post="RNA transcriptionCell19812384785810.1016/0092-8674(81)90449-96261960 7.ReichSet al.Structural insight into cap-snatching and RNA"/>
 <result pre="danger of its generation and spreadPLoS Comput. Biol.20073e24010.1371/journal.pcbi.003024018069885 11.SmithAMPerelsonASInfluenza A" exact="virus infection" post="kinetics: quantitative data and modelsWiley Interdiscip. Rev. Syst. Biol."/>
 <result pre="of its generation and spreadPLoS Comput. Biol.20073e24010.1371/journal.pcbi.003024018069885 11.SmithAMPerelsonASInfluenza A virus" exact="infection" post="kinetics: quantitative data and modelsWiley Interdiscip. Rev. Syst. Biol."/>
 <result pre="data and modelsWiley Interdiscip. Rev. Syst. Biol. Med.2011342944510.1002/wsbm.12921197654 12.Centers for" exact="Disease" post="Control and Prevention. Influenza positive tests reported to CDC"/>
 <result pre="laboratories and ILI activity, national summary. CDChttps://gis.cdc.gov/grasp/fluview/fluportaldashboard.html (2018). 13.Centers for" exact="Disease" post="Control and Prevention. Percentage of visits for ILI, national"/>
 <result pre="between and within scales: environmental persistence and within-host fitness of" exact="avian influenza" post="virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for Disease Control and Prevention."/>
 <result pre="within-host fitness of avian influenza virusesProc. Biol. Sci.20142812013305110.1098/rspb.2013.305124898369 16.Centers for" exact="Disease" post="Control and Prevention. Archived estimated influenza illnesses, medical visits,"/>
 <result pre="in the United States—2017–2018 influenza season (CDC, 2019). 17.Centers for" exact="Disease" post="Control and Prevention. Influenza antiviral medications: clinician summary (CDC,"/>
 <result pre="impact of low-efficacy influenza vaccinesProc. Natl Acad. Sci. USA20181155151515610.1073/pnas.180247911529712866 23.GranwehrBPIn" exact="acute" post="uncomplicated influenza, single-dose baloxavir decreased time to symptom relief"/>
 <result pre="23–March 16, 2020MMWR. Morbidity Mortal. Wkly. Rep.20206941141510.15585/mmwr.mm6914e1 33.VegvariCet al.How can" exact="viral" post="dynamics models inform endpoint measures in clinical trials of"/>
 <result pre="models inform endpoint measures in clinical trials of therapies for" exact="acute" post="viral infections?PLoS ONE201611e015823710.1371/journal.pone.015823727367230 34.Hirotsu, N. et al. Baloxavir marboxil"/>
 <result pre="inform endpoint measures in clinical trials of therapies for acute" exact="viral" post="infections?PLoS ONE201611e015823710.1371/journal.pone.015823727367230 34.Hirotsu, N. et al. Baloxavir marboxil in"/>
 <result pre="Bayesian computational methodsStat. Comput.2012221167118010.1007/s11222-011-9288-2 40.JiangHet al.Preliminary epidemiologic assessment of human" exact="infections" post="with highly pathogenic avian influenza A (H5N6) virus, ChinaClin."/>
 <result pre="40.JiangHet al.Preliminary epidemiologic assessment of human infections with highly pathogenic" exact="avian influenza" post="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods"/>
 <result pre="A (H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of" exact="acute" post="respiratory viral infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir"/>
 <result pre="(H5N6) virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of acute" exact="respiratory" post="viral infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir marboxil"/>
 <result pre="virus, ChinaClin. Infect. Dis.20176538338810.1093/cid/cix33428407105 41.LesslerJet al.Incubation periods of acute respiratory" exact="viral" post="infections: a systematic reviewLancet Infect. Dis.2009929130010.1016/S1473-3099(09)70069-619393959 42.KoszalkaPTilmanisDRoeMVijaykrishnaDHurtABaloxavir marboxil susceptibility"/>
 <result pre="Asia-Pacific, 2012–2018Antiviral Res.2019164919610.1016/j.antiviral.2019.02.00730771405 43.Keeling, M. J. &amp;amp; Rohani, P. Modeling" exact="Infectious" post="Diseases in Humans and Animals (Princeton Univ. Press, 2011)."/>
 <result pre="2012–2018Antiviral Res.2019164919610.1016/j.antiviral.2019.02.00730771405 43.Keeling, M. J. &amp;amp; Rohani, P. Modeling Infectious" exact="Diseases" post="in Humans and Animals (Princeton Univ. Press, 2011). 44.GoldsteinEViboudCCharuVLipsitchMImproving"/>
 <result pre="Biol.201713e100574910.1371/journal.pcbi.100574929049288 46.Xiang, Y., Gubian, S., Suomela, B. &amp;amp; Hoeng, J." exact="Generalized" post="simulated annealing for global optimization: the GenSA package. R"/>
</results>
